Cingulate reports Q2 2026 results, updates CTx-1301 CMC and NDA resubmission plansAug 13Quarterly updateCingulate Inc.
Cingulate posts Phase 3 CTx-1301 classroom results in ADHD, more than two years after trial endedJul 2Trial updateCingulate Inc.
Sign inSign in